Menopause : full guideline / National Collaborating Centre for Women's and Children's Health (Great Britain).

Format:

Book

Author/Creator:

National Collaborating Centre for Women's and Children's Health (Great Britain), author, issuing body.

Language:

English

Subjects (All):

Menopause.

Physical Description:

1 online resource (283 pages) : illustrations

Edition:

First edition.

Place of Publication:

London : National Collaborating Centre for Women's and Children's Health, 2015.

Summary:

In summary, a large number of women in the UK experience menopausal symptoms which, in many cases, can significantly affect their quality of life. It is probable that a minority of these women seek medical treatment and for those who do there is considerable variation in the help available, with many being told that the symptoms will get better with time. Since symptoms may often continue for 7 years or more, this advice is inappropriate and help should be offered where possible. Women need to know about the available options and their risks and benefits, and be empowered to become part of the decision-making process. The need for this guideline was recognised by the Department of Health and aims to provide advice for both healthcare professionals and women regarding the menopause and the way symptom relief can be achieved. It not only covers women who go through the menopause in middle age, but also those with premature ovarian insufficiency (POI) and for whom hormones are not appropriate, including women with, or at high risk of, breast cancer. It covers the diagnosis and optimal clinical management of menopause-related symptoms, including hormonal and non-hormonal therapies. Attention is also given to the contentious issue of the impact of hormone replacement therapy (HRT) on chronic disease prevention, although other, established treatments for cardiovascular disease (CVD) and osteoporosis, in particular, are not covered.

Contents:

Introduction

1. Guideline summary

1.1. Guideline Development Group membership, NCC-WCH staff and acknowledgements

1.2. Care algorithm

1.3. Recommendations

1.4. Research recommendations

1.5. Other versions of the guideline

1.6. Schedule for updating the guideline

2. Development of the guideline

2.1. What is a NICE clinical guideline?

2.2. Remit

2.3. Who developed this guideline?

2.4. What this guideline covers

2.5. What this guideline does not cover

2.6. Relationships between the guideline and other NICE guidance

3. Guideline development methodology

3.1. Developing the review questions and protocols

3.2. Searching for evidence

3.3. Reviewing and synthesising the evidence

3.4. Developing recommendations

4. Individualised care

4.1. Recommendations

5. Diagnosis of perimenopause and menopause

5.1. Introduction

5.2. Review question

5.3. Description of included studies

5.4. Evidence profiles

5.5. Evidence statements

5.6. Health economics profile

5.7. Evidence to recommendations

5.8. Recommendations

6. Classification systems for the diagnosis of menopause

6.1. Introduction

6.2. Review question

6.3. Description of included studies

6.4. Evidence profiles

6.5. Evidence statements

6.6. Health economics profile

6.7. Evidence to recommendations

7. Information and advice

7.1. Introduction

7.2. Review question

7.3. Description of included studies

7.4. Evidence profiles

7.5. Evidence statements

7.6. Health economics profile

7.7. Evidence to recommendations

7.8. Recommendations

8. Managing short-term symptoms

8.1. Introduction

8.2. Management of vasomotor symptoms, mood changes, musculoskeletal problems and sexual disorders

8.3. Urogenital atrophy

9. Review and referral

9.1. Introduction

9.2. Review question

9.3. Description of included studies

9.4. Evidence profiles

9.5. Evidence statements

9.6. Health Economics profile

9.7. Evidence to recommendations

9.8. Recommendations

10. Starting and stopping hormone replacement therapy (HRT)

10.1. Introduction

10.2. Review question

10.3. Description of included studies

10.4. Evidence profiles

10.5. Evidence statements

10.6. Health economics profile

10.7. Evidence to recommendations

10.8. Recommendations

11. Long-term benefits and risks of hormone replacement therapy (HRT)

11.1. Venous thromboembolism

11.2. Cardiovascular disease

11.3. Development of Type 2 diabetes

11.4. Type 2 diabetes management - control of blood sugar

11.5. Breast cancer

11.6. Osteoporosis

11.7. Dementia

11.8. Loss of muscle mass ('sarcopenia')

12. Premature ovarian insufficiency

12.1. Introduction

12.2. Diagnosis of premature ovarian insufficiency

12.3. Management of premature ovarian insufficiency

13. References

14. Glossary and abbreviations

Appendices

Appendix A. Scope

Appendix B. Stakeholders

Appendix C. Declarations of interest

Appendix D. Review protocols

Appendix E. Search strategies

Appendix F. Prisma flow charts

Appendix G. Excluded studies

Appendix H. Evidence tables

Appendix I. GRADE profiles

Appendix J. Forest plots

Appendix K. Network meta-analysis of interventions in the pharmacological and non-pharmacological treatment of short-term symptoms for women in menopause

Appendix L. Health economics

Appendix M. Absolute risk references.

Notes:

Includes bibliographical references.

Description based on publisher supplied metadata and other sources.